|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway (DCC 2-2) |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6382-12
|
||||||||
|
6. House ID# 314000000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly James |
Date | 10/19/2023 11:07:14 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordability; COVID Commercialization; Affordable Care Act; Telehealth; Mental Health; Youth Mental Health; Health Equity; Site Neutrality/Site Neutral Payment Reform; Fair Hospital Billing; Appropriations; Health Savings Accounts; Prior Authorization; Transparency in Coverage; Surprise Billing; Preventive Services
HR 3417 (118th Congress), FAIR Act, by Rep. Kevin Hern (R-OK). To ensure fair billing practices for items and services furnished by off-campus outpatient departments of a provider.
HR 3561 (118th Congress), the Patient Act of 2023, by Rep. Cathy McMorris Rodgers (R-WA). To promote hospital and insurer price transparency.
HR 4507 (118th Congress), Transparency in Coverage Act of 2023, by Rep. Bob Good (R-VA). To amend the Employee Retirement Income Security Act of 1974 to promote transparency in health coverage and reform pharmacy benefit management services with respect to group health plans.
HR 4508 (118th Congress), Hidden Fee Disclosure Act, by Rep. Joe Courtney (D-CT). To amend the Employee Retirement Income Security Act of 1974 to clarify and strengthen the application of certain employer-sponsored health plan disclosure requirements.
HR 4509 (118th Congress), Transparency in Billing Act, by Rep. Virginia Foxx (R-NC). To amend the Employee Retirement Income Security Act of 1974 to require group health plans and health insurance issuers offering group health insurance coverage to only pay claims submitted by hospitals that have in place policies and procedures to ensure accurate billing practices.
HR 4531 (118th Congress), Support for Patients and Communities Reauthorization Act, by Rep. Brett Guthrie (R-KY). To reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment.
HR 4822 (118th Congress), Health Care Price Transparency Act of 2023, by Rep. Jason Smith (R-MO). To improve price transparency with respect to certain health care services.
HR 5378 (118th Congress), Lower Costs, More Transparency Act, by Rep. Cathy McMorris Rodgers (R-WA). To promote price transparency in the health care sector.
HR 5687 (118th Congress), HSA Modernization Act of 2023, by Rep. Beth Van Duyne (R-TX). To amend the Internal Revenue Code of 1986 to modernize health savings accounts.
HR 5688 (118th Congress), Bipartisan HSA Improvement Act of 2023, by Rep. Lloyd Smucker (R-PA). To amend the Internal Revenue Code of 1986 to improve health savings accounts.
S 652 (118th Congress), Safe Step Act, by Sen. Lisa Murkowski (R-AK). To amend the Employee Retirement Income Security Act of 1974 to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol.
S 1869 (118th Congress), SITE Act, by Sen. Mike Braun (D-HI). To amend title XVIII of the Social Security Act and title XXVII of the Public Health Service Act to ensure fair billing practice for items and services furnished by off-campus hospital locations, to amend such title XVIII to provide for payments for graduate nursing education costs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Executive Office of the President (EOP), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Provider Directories; Medicaid Redeterminations; Draft Duals Legislation; IRA Copay Smoothing; MA Health Equity Index
HR 1613/S 1038 (118th Congress), Drug Price Transparency in Medicaid Act of 2023, by Rep. Earl Carter (R-GA) and Sen. Peter Welch (D-VT). To amend title XIX of the Social Security Act to improve transparency and prevent the use of spread pricing and related practices in the Medicaid program.
H.R.3284 (118th Congress), Providers and Payers COMPETE Act, by Rep. Michael Burgess (R-TX). To require the Secretary of Health and Human Services to submit an annual report on the impact of certain Medicare regulations on provider and payer consolidation.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines
S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin.
S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |